Search - tctmd.com

Displaying 1 - 20 of 99

Sort: Relevancy | Date

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

What’s Going to Be Hot at TCT 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

News Conference News TCT 2024

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

Yael L. Maxwell

November 07, 2024

PAD Patients’ Views on Decisions and Outcomes Hinge on Sex, Race/Ethnicity: ELEGANCE

News Conference News TCT 2024

PAD Patients’ Views on Decisions and Outcomes Hinge on Sex, Race/Ethnicity: ELEGANCE

November 04, 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

November 01, 2024

Embolic Protection Benefits Varied by Geography in PROTECTED TAVR

News Conference News TCT 2024

Embolic Protection Benefits Varied by Geography in PROTECTED TAVR

October 31, 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR

News Conference News TCT 2024

TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR

Michael O'Riordan

October 29, 2024

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

News Conference News TCT 2024

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

October 28, 2024

LAAO Outcomes Similar Regardless of Operator’s Specialty

News Conference News TCT 2024

LAAO Outcomes Similar Regardless of Operator’s Specialty

October 27, 2024

What’s Going to Be Big at TCT 2024?

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

CLASP IID at 1 Year: Good Results With Both Pascal, MitraClip for Mitral TEER

News Conference News TCT 2023

CLASP IID at 1 Year: Good Results With Both Pascal, MitraClip for Mitral TEER

October 26, 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

October 25, 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

October 24, 2023

OCT, IVUS Both Seem to Be Good Options for Complex Coronary Lesions

News Conference News TCT 2023

OCT, IVUS Both Seem to Be Good Options for Complex Coronary Lesions

October 23, 2023

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

News Conference News TCT 2022

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

September 19, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.